FENNEC PHARMACEUTICALS INC. (FENC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
FENC currently has 34.3M outstanding shares. with limited dilution risk as only 2.74M additional shares (8.0%) are authorized for issuance. The company has significantly diluted shareholders by 25.44% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 34.3M shares outstanding |
34M | 2.7M |
| Mar 27, 2026 |
10-K filing | 34.2M shares outstanding |
34M | 2.9M |
| Nov 18, 2025 |
8-K filing: Fennec Pharmaceuticals Inc. closed an offering of 670,000 common shares at a price of $7.50 per share, resulting in gross proceeds of $5,025,000. ($5.03M proceeds) |
28M | 9.2M |
| Nov 17, 2025 |
8-K filing: Fennec Pharmaceuticals Inc. entered into an underwriting agreement to issue and sell 4,666,667 common shares at $7.50 per share, with the underwriters purchasing them at $6.975 per share, and granted the underwriters an option to purchase up to an additional 700,000 shares; the offering is expected to close on November 17, 2025. |
28M | 9.2M |
| Nov 13, 2025 |
10-Q filing | 27.9M shares outstanding |
28M | 9.2M |
| Aug 14, 2025 |
10-Q filing | 27.7M shares outstanding |
28M | 9.4M |
| May 14, 2025 |
10-Q filing | 27.6M shares outstanding |
28M | 9.5M |
| Mar 26, 2025 |
10-K filing | 27.3M shares outstanding |
27M | 9.8M |
| Nov 08, 2024 |
10-Q filing | 27.4M shares outstanding |
27M | 9.7M |
| Aug 13, 2024 |
10-Q filing | 27.3M shares outstanding |
27M | 9.8M |
| May 14, 2024 |
10-Q filing | 27.0M shares outstanding |
27M | 10M |
| Mar 29, 2024 |
10-K filing | 26.6M shares outstanding |
27M | 11M |
| Nov 09, 2023 |
10-Q filing | 26.6M shares outstanding |
27M | 10M |
| Nov 09, 2023 |
S-3 filing: This is an at the market offering of common stock with an aggregate offering price of up to $25,000,000 through H.C. Wainwright& Co., LLC as sales agent. |
26M | 11M |
| Aug 07, 2023 |
10-Q filing | 26.5M shares outstanding |
26M | 6.7M |
| May 12, 2023 |
10-Q filing | 26.6M shares outstanding |
27M | 6.6M |
| Mar 29, 2023 |
10-K filing | 26.3M shares outstanding |
26M | 6.9M |
| Dec 01, 2022 |
S-3 filing: This prospectus relates to the possible resale of up to 3,914,850 of our common shares from time to time in one or more offerings by the selling stockholder named herein. |
26M | 6.9M |
| Nov 14, 2022 |
10-Q filing | 26.1M shares outstanding |
26M | 0 |
| Sep 26, 2022 |
8-K filing: Fennec Pharmaceuticals Inc. completed the second closing of its financing transaction with Petrichor Opportunities Fund I LP, issuing a $20,000,000 tranche of senior secured floating rate convertible notes convertible at $7.89 per share and warrants to purchase 55,498 common shares exercisable at $8.11. |
26M | 0 |
| Aug 22, 2022 |
8-K filing: Fennec Pharmaceuticals Inc. completed the first closing of a financing transaction with Petrichor Opportunities Fund I LP, issuing $5,000,000 of senior secured floating rate convertible notes and warrants to purchase 55,498 Fennec common shares. |
26M | 0 |
| Aug 12, 2022 |
10-Q filing | 26.1M shares outstanding |
26M | 0 |
| Aug 01, 2022 |
8-K filing: Fennec Pharmaceuticals Inc. entered into a Securities Purchase Agreement with Petrichor Opportunities Fund I LP for the issuance of up to $45,000,000 of senior secured floating rate convertible notes in multiple tranches, with an initial tranche of $5,000,000 convertible at $8.11 per share and warrants to purchase 55,498 Fennec common shares at $8.11 per share. |
26M | 0 |
| May 12, 2022 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |
| Feb 28, 2022 |
10-K filing | 26.0M shares outstanding |
26M | 0 |
| Nov 10, 2021 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |
| Aug 10, 2021 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |
| May 13, 2021 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |
| Mar 30, 2021 |
10-K filing | 26.0M shares outstanding |
26M | 0 |
| Nov 16, 2020 |
10-Q filing | 25.8M shares outstanding |
26M | 0 |
| Oct 30, 2020 |
S-3 filing: This is an S-3 filing for the registration of common shares. |
25M | 0 |
| Aug 05, 2020 |
10-Q filing | 25.4M shares outstanding |
25M | 0 |
| May 14, 2020 |
10-Q filing | 25.4M shares outstanding |
25M | 0 |
| May 04, 2020 |
8-K filing: Fennec Pharmaceuticals Inc. completed an underwritten public offering of 4,800,000 common shares at a price of $6.25 per share, with the underwriters having an option to purchase an additional 720,000 shares. |
19M | 0 |
| Feb 14, 2020 |
10-K filing | 18.9M shares outstanding |
19M | 0 |